TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Mesoblast Limited
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

Mesoblast reported a 37% increase in Ryoncil® gross revenue for Q4 2025, expecting over $30 million in sales, and continues developing cellular medicines for inflammatory conditions.

Insights
IBM   neutral

Mentioned as a key player without specific details about their current performance or innovations


MESO   positive

Company reported strong revenue growth, continued product development, and expanding market presence in cellular medicine therapies